Altimmune Inc (ALT)

$5.24 -0.07 (-1.32%)
Market Cap 554.06M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 2,583,800
Avg Vol 2,988,386
Day's Range N/A - N/A
Shares Out 104.34M
Stochastic %K 76%
Beta -0.03
Analysts Strong Sell
Price Target $17.88

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
Bealsta
Bealsta Dec. 7 at 1:25 AM
$ALT very
0 · Reply
Designed2Gain
Designed2Gain Dec. 7 at 1:15 AM
$ALT Trending again and SpammyRich and his band of fake accounts managing to spam post enough to shed doubt on the real science. You have to love the ST co-founder Howies band of sponsored FUDs on this one board. Even with his backing, they can't slander the real science and the inevitable future of Altimmune.
1 · Reply
quickaspeter
quickaspeter Dec. 7 at 12:57 AM
$ALT Best-in-Class!!! 💥🚀💰💰💰
0 · Reply
Dadschuh14
Dadschuh14 Dec. 7 at 12:57 AM
$ALT man these accounts that has popped up are insane. It’s weird I see the same accounts that have been here a long time battling it out with these other accounts (who knows what to call them at this point). It’s clear these accounts are here to spread false information that unfortunately all the new people coming to the board trying to figure out what is going on are going to see. This shows we are on the cusp of price discovery and big news. I see you OG longs, fight the fight boys! ✊🏽😎
3 · Reply
quickaspeter
quickaspeter Dec. 7 at 12:56 AM
$ALT Best-in-Class…let’s go!!! 💥🚀💰 @Groggok Pemvidutide does not only have weight loss properties but also muscle sparing properties and that’s why it’s the BEST IN CLASSof weight loss GLP-1s
0 · Reply
Wolly99
Wolly99 Dec. 7 at 12:52 AM
$ALT bullish for ALT
1 · Reply
Geohotventures
Geohotventures Dec. 7 at 12:51 AM
$ALT really appreciative of the lineup mentioned below!
0 · Reply
BigBALLS1111
BigBALLS1111 Dec. 7 at 12:40 AM
$ALT $VKTX fully agree but you can still make money
1 · Reply
scoobydoo16
scoobydoo16 Dec. 7 at 12:38 AM
$ALT Look at the last 20 or so ”posters” who “liked” my last post. Never heard of any of these posters. Why? Because they’re dummy accounts produced by BioKaren and howie. Just more proof that howie and richie are one and the same. Maybe your employer might want to look into this little obsession? @Stocktwits
1 · Reply
kadinnguyen
kadinnguyen Dec. 7 at 12:30 AM
$ALT my understanding is that eop2 meeting isn't dependent on 48 wks data. If it's done on time great. They'll go over it. If not, I think they will have the meeting this month regardless as it's an in-person meeting and they will take whatever date given by the FDA. On the same note, they will have feedback, or most of it immediately imo.
0 · Reply
Latest News on ALT
Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 5 days ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 10 days ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 16 days ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 22 days ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 25 days ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 4 weeks ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 4 weeks ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 4 weeks ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 4 weeks ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 5 weeks ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 6 weeks ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 2 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 2 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 2 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 2 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 2 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 3 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 3 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 3 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 4 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:44 PM EDT - 4 months ago

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 13, 2025, 2:57 PM EDT - 4 months ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Aug 12, 2025, 7:00 AM EDT - 4 months ago

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Aug 11, 2025, 7:30 AM EDT - 4 months ago

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 5, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Jul 19, 2025, 2:30 PM EDT - 5 months ago

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Bealsta
Bealsta Dec. 7 at 1:25 AM
$ALT very
0 · Reply
Designed2Gain
Designed2Gain Dec. 7 at 1:15 AM
$ALT Trending again and SpammyRich and his band of fake accounts managing to spam post enough to shed doubt on the real science. You have to love the ST co-founder Howies band of sponsored FUDs on this one board. Even with his backing, they can't slander the real science and the inevitable future of Altimmune.
1 · Reply
quickaspeter
quickaspeter Dec. 7 at 12:57 AM
$ALT Best-in-Class!!! 💥🚀💰💰💰
0 · Reply
Dadschuh14
Dadschuh14 Dec. 7 at 12:57 AM
$ALT man these accounts that has popped up are insane. It’s weird I see the same accounts that have been here a long time battling it out with these other accounts (who knows what to call them at this point). It’s clear these accounts are here to spread false information that unfortunately all the new people coming to the board trying to figure out what is going on are going to see. This shows we are on the cusp of price discovery and big news. I see you OG longs, fight the fight boys! ✊🏽😎
3 · Reply
quickaspeter
quickaspeter Dec. 7 at 12:56 AM
$ALT Best-in-Class…let’s go!!! 💥🚀💰 @Groggok Pemvidutide does not only have weight loss properties but also muscle sparing properties and that’s why it’s the BEST IN CLASSof weight loss GLP-1s
0 · Reply
Wolly99
Wolly99 Dec. 7 at 12:52 AM
$ALT bullish for ALT
1 · Reply
Geohotventures
Geohotventures Dec. 7 at 12:51 AM
$ALT really appreciative of the lineup mentioned below!
0 · Reply
BigBALLS1111
BigBALLS1111 Dec. 7 at 12:40 AM
$ALT $VKTX fully agree but you can still make money
1 · Reply
scoobydoo16
scoobydoo16 Dec. 7 at 12:38 AM
$ALT Look at the last 20 or so ”posters” who “liked” my last post. Never heard of any of these posters. Why? Because they’re dummy accounts produced by BioKaren and howie. Just more proof that howie and richie are one and the same. Maybe your employer might want to look into this little obsession? @Stocktwits
1 · Reply
kadinnguyen
kadinnguyen Dec. 7 at 12:30 AM
$ALT my understanding is that eop2 meeting isn't dependent on 48 wks data. If it's done on time great. They'll go over it. If not, I think they will have the meeting this month regardless as it's an in-person meeting and they will take whatever date given by the FDA. On the same note, they will have feedback, or most of it immediately imo.
0 · Reply
biolover
biolover Dec. 7 at 12:23 AM
$ALT $VKTX since u r bio tech guru and your brain can handle a couple of data points beyond profanity .. show us in comparison to other agents why u state pamvi is BIC in MASH ? Dont show me the stupid liver fat reduction on MRI from 14 pt arm trial like the other clueless do here ? Show us what support BIc in MASH ? Who else did 24 wk biopsy trial in MASH ?
2 · Reply
brambo13
brambo13 Dec. 7 at 12:17 AM
$ALT Saturday Saturday Saturday nights alright
0 · Reply
MaryDiaz
MaryDiaz Dec. 7 at 12:15 AM
"$WMT $COCK.X $ALT (WMT)Walmart Is Approaching a Breakout Zone — Major Move Ahead? Walmart tests key resistance at $115-117. Breakout targets $122-125. Rejection risks drop to $112-$105. Stop-loss: long below $111, short above $118. Bullish momentum & strong fundamentals support breakout."
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 7 at 12:13 AM
$ALT $VKTX 1. His holdings over time have only gone up. He is not hopping off. 2. He understood he isn't the person the company needs to partner/buyout. He has the personality of a lemur and it has been a problem. He doesn't want to be in his own way of becoming a billionaire. 3. His position has absolutely nothing to do with the science. The drug is best in class in MASH and it only took 24 weeks to show powerful effect.
2 · Reply
Corpkcots
Corpkcots Dec. 7 at 12:11 AM
$ALT Bears and FUDsters beware, ALT is unstoppable! That’s what happens when you have the best science and best in class molecule. ALT is headed to the moon! Go ALT, $15B
0 · Reply
Bealsta
Bealsta Dec. 7 at 12:09 AM
$ALT
0 · Reply
TrustButVerifi
TrustButVerifi Dec. 7 at 12:04 AM
$ALT $VKTX why the fk is Vipin a 30 yr scammer hopping off the bus if this precious bio Alt (still waiting on Covid nasal spray) is such a jewel? Pemvi was bought under his reign from Spotfire. Fool me once! Shame on U Fool me twice Fk U Only Mash you re get from Pemvi is potato Nothin else ! Biotech_Clieless !
5 · Reply
Groggok
Groggok Dec. 7 at 12:01 AM
$ALT Dangerous loss of muscle caused by injections may put older people at risk of frailty, study finds https://apple.news/AZxZNVlRtR7ue8QTH12cJFw
1 · Reply
Drewpac
Drewpac Dec. 7 at 12:00 AM
$ALT I suspect the SP to bomb on release of 48wk data... that is just how this story has gone time and time over again with ALT and the cok sukr shorts like GS who silently kill the dtock and accumulate. Then there will be the FDA meeting... this will pull the SP back to baseline reality... and then several fireside chats to defend what just happened instead of what is about to happen. SP value will not be its fullest potential until it is backed by a sale price. Plain and simple. Comps would have pemvi worth 12-18B. Imo. Now, 48week data that is VERY good/great coupled with FDA eop2 similar to the tone of the eop2 obesity and either BTD or AA would kill the shorts for good. Pemv/ALT would surge to 5 billion MC overnight and possibly 7+ B mc until settling down at 3B. This would give comp to BP to writeca check for 18B. Then its hookrs and cocaine
2 · Reply
Needmoney_Gargdaddy
Needmoney_Gargdaddy Dec. 6 at 11:57 PM
$ALT Where did all these nobody bears come from? Must be squeezing their cheeks with fear.
1 · Reply
guhruuu
guhruuu Dec. 6 at 11:48 PM
$ALT
0 · Reply
JoeDirty
JoeDirty Dec. 6 at 11:38 PM
$ALT All this noise I have to suffer from just to try to double some calls this week. I should get an award for interacting with you people.
0 · Reply